source
- Vaxcyte's experimental pneumococcal vaccine meets primary endpoints in Phase 3 trialVaxcyte announced that its experimental pneumococcal vaccine, VAX-31, achieved the primary endpoints in a Phase 3 trial. The study enrolled just over 3,500 adults aged 50 and older who were random…
- Nobel prize honors scientists who pioneered light-activated gene therapy technologyThree researchers received this year’s Nobel Prize in medicine for creating optogenetics, a technique that uses light to steer nerve activity. The award recognizes their foundational work that has…